Pfizer CEO Discusses Tariffs and Drug Pricing with Trump Administration

Pfizer CEO Albert Bourla revealed ongoing discussions with the TRUMP administration regarding potential tariffs and Most Favored Nations pricing for pharmaceuticals. The dialogue stems from a relationship forged during the COVID-19 pandemic, when collaboration accelerated vaccine development.

Bourla characterized President Trump as understanding industry dynamics, though not immersed in technical details. The CEO noted a proposed phased approach to tariffs, starting with minimal rates before potential increases. This aligns with broader administration efforts to address drug pricing and domestic production concerns.

The pharmaceutical industry awaits the outcome of a government investigation that could shape future trade and pricing policies. These developments occur against the backdrop of Trump's reelection campaign, where healthcare economics remain a central issue.